| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
Basic Science Investigations |
1 Nuclear Physics Enterprises, Cherry Hill, New Jersey
2 Garden State Cancer Center, Belleville, New Jersey
3 Vanderbilt University School of Medicine, Nashville, Tennessee
4 CDE Dosimetry Services, Inc., Knoxville, Tennessee
Calculated red marrow absorbed dose in patients receiving radioimmunotherapy (RAIT) has not been highly predictive of the dose-limiting hematologic toxicity observed in many patient populations studied. Because patients receiving the same red marrow dose often experience different grades of toxicity, other factors might help predict the different grades of toxicity observed. One such factor may be the plasma FLT3-L (FMS-related tyrosine kinase 3 ligand, hematopoiesis stimulatory cytokine) level, which has been shown to be a better indicator of recovery of progenitor cells and, thus, red marrow radiosensitivity (because during the recovery period the progenitor cells are hyperproliferative and potentially more radiosensitive) for patients treated with previous chemotherapy than peripheral blood counts. Methods: Red marrow radiation doses were determined for 30 patients (20 male, 10 female; all without bone marrow or bone involvement; 19 had prior chemotherapy) after receiving 131I RAIT (activity range, 2.1–8.9 GBq) for treatment of solid cancers known to produce carcinoembryonic antigen. Radiation dose estimates were calculated using 2 different methods of red marrow cumulated activity and red marrow-to-blood activity concentration ratio determinations for 2 dosimetric models: using both male and female and male-only masses and S values. Highest platelet toxicity grade at nadir (PTG), percentage platelet decrease (PPD) in counts, and platelet nadir (PN) counts were measured. FLT3-L levels (pg/mL) were determined by immunoassay before treatment; a normal FLT3-L level was assumed to be 80 pg/mL. The red marrow radiation doses (cGy) were adjusted for the patient’s FLT3-L level when the patient’s cytokine level exceeded the normal value. Marrow doses and FLT3-L–adjusted marrow doses were correlated with PTG, PPD, PN, and 1/PN. Administered activity, administered activity per unit body weight, and total body radiation dose were also correlated with these hematologic toxicity measures. Results: All red marrow dose calculation schemes resulted in essentially the same correlations for a given hematologic toxicity measure. Poor correlations were observed between administered activity, administered activity per unit body weight, total body radiation dose, or red marrow radiation dose and PTG, PPD, PN, and 1/PN. All correlations improved greatly when the various predictors of toxicity were adjusted for the patient’s FLT3-L level. The highest correlation observed was between red marrow dose or total body dose and 1/PN (r = 0.86). Using an unadjusted red marrow dose to predict toxicity 
grade 3, there were 8 true-positive, but 13 false-positive cases with 9 true-negatives. However, using a FLT3-L–adjusted red marrow dose, there were 8 true-positives, but only 2 false-positives and 20 true-negatives. Conclusion: FLT3-L–adjusted red marrow radiation doses provide improved correlation with hematologic toxicity. Thus, elevated FLT3-L plasma levels before RAIT may indicate increased radiosensitivity of the bone marrow, and use of this measurement to adjust calculated red marrow or total body radiation doses may provide significantly better prediction of toxicity than radiation dose alone, leading to a patient-specific administered activity prescription that will deliver radiation doses to diseased tissues sufficient to produce an effective treatment outcome at acceptable toxicity levels.
Key Words: dosimetry • Flt3-L • hematologic toxicity • radioimmunotherapy • radionuclide therapy • red marrow dosimetry • thrombocytopenia
This article has been cited by other articles:
|
|
 |
|
  G. Dancey, J. Violet, A. Malaroda, A. J. Green, S. K. Sharma, R. Francis, S. Othman, S. Parker, J. Buscombe, N. Griffin, et al. A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma Clin. Cancer Res., December 15, 2009; 15(24): 7701 - 7710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Brindle, A. A. Trindade, A. P. Shah, D. W. Jokisch, P. W. Patton, J. C. Pichardo, and W. E. Bolch Linear Regression Model for Predicting Patient-Specific Total Skeletal Spongiosa Volume for Use in Molecular Radiotherapy Dosimetry J. Nucl. Med., November 1, 2006; 47(11): 1875 - 1883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. D. Volkow, G.-J. Wang, F. Telang, J. S. Fowler, J. Logan, A.-R. Childress, M. Jayne, Y. Ma, and C. Wong Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J. Neurosci., June 14, 2006; 26(24): 6583 - 6588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Berndorff, S. Borkowski, S. Sieger, A. Rother, M. Friebe, F. Viti, C. S. Hilger, J. E. Cyr, and L. M. Dinkelborg Radioimmunotherapy of Solid Tumors by Targeting Extra Domain B Fibronectin: Identification of the Best-Suited Radioimmunoconjugate Clin. Cancer Res., October 1, 2005; 11(19): 7053s - 7063s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Brouwers, P. F.A. Mulders, P. H.M. de Mulder, W. J.M. van den Broek, W. C.A.M. Buijs, C. Mala, F. B.M. Joosten, E. Oosterwijk, O. C. Boerman, F. H.M. Corstens, et al. Lack of Efficacy of Two Consecutive Treatments of Radioimmunotherapy With 131I-cG250 in Patients With Metastasized Clear Cell Renal Cell Carcinoma J. Clin. Oncol., September 20, 2005; 23(27): 6540 - 6548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Siegel, R. B. Sparks, R. M. Sharkey, B. W. Wessels, W. E. Bolch, L. G. Bouchet, H. B. Breitz, R. F. Meredith, G. Sgouros, and M. G. Stabin Blood-Based Red Marrow Dosimetry: Where's the Beef? J. Nucl. Med., August 1, 2005; 46(8): 1404 - 1406. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Scott Radioimmunotherapy of Prostate Cancer: Does Tumor Size Matter? J. Clin. Oncol., July 20, 2005; 23(21): 4567 - 4569. [Full Text] [PDF]
|
|
|
|
|
|
S. Shen, S. J. DeNardo, C. M. Richman, A. Yuan, C. H. Siantar, R. T. O'Donnell, L. A. Kroger, and G. L. DeNardo Planning Time for Peripheral Blood Stem Cell Infusion After High-Dose Targeted Radionuclide Therapy Using Dosimetry J. Nucl. Med., June 1, 2005; 46(6): 1034 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Goldenberg and R. M. Sharkey Radioimmunotherapy of Non-Hodgkin's Lymphoma Revisited J. Nucl. Med., February 1, 2005; 46(2): 383 - 384. [Full Text] [PDF]
|
|
|
|
|
|
G. Sgouros Dosimetry of Internal Emitters J. Nucl. Med., January 1, 2005; 46(1_suppl): 18S - 27S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Sharkey and D. M. Goldenberg Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies J. Nucl. Med., January 1, 2005; 46(1_suppl): 115S - 127S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. W. Wessels, W. E. Bolch, L. G. Bouchet, H. B. Breitz, G. L. DeNardo, R. F. Meredith, M. G. Stabin, and G. Sgouros Bone Marrow Dosimetry Using Blood-Based Models for Radiolabeled Antibody Therapy: A Multiinstitutional Comparison J. Nucl. Med., October 1, 2004; 45(10): 1725 - 1733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Sharkey, A. Brenner, J. Burton, G. Hajjar, S. P. Toder, A. Alavi, A. Matthies, D. E. Tsai, S. J. Schuster, E. A. Stadtmauer, et al. Radioimmunotherapy of Non-Hodgkin's Lymphoma with 90Y-DOTA Humanized Anti-CD22 IgG (90Y-Epratuzumab): Do Tumor Targeting and Dosimetry Predict Therapeutic Response? J. Nucl. Med., December 1, 2003; 44(12): 2000 - 2018. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
